Patient‐reported tolerability of veliparib combined with cisplatin and etoposide for treatment of extensive stage small cell lung cancer: Neurotoxicity and adherence data from the ECOG ACRIN cancer research group E2511 phase II randomized trial

OBJECTIVES: The ECOG‐ACRIN Cancer Research Group trial E2511 recently demonstrated a potential benefit for the addition of veliparib to cisplatin‐etoposide (CE) in patients with extensive stage small cell lung cancer (ES‐SCLC) in a phase II randomized controlled trial. Secondary trial endpoints incl...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Cancer Med
Glavni autori: Steffen McLouth, Laurie E., Zhao, Fengmin, Owonikoko, Taofeek K., Feliciano, Josephine L., Mohindra, Nisha A., Dahlberg, Suzanne E., Wade, James L., Srkalovic, Gordan, Lash, Bradley W., Leach, Joseph W., Leal, Ticiana A., Aggarwal, Charu, Cella, David, Ramalingam, Suresh S., Wagner, Lynne I.
Format: Artigo
Jezik:Inglês
Izdano: John Wiley and Sons Inc. 2020
Teme:
Clinical Cancer Research
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7571824/
https://ncbi.nlm.nih.gov/pubmed/32860331
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.3416
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items